|Awarded On||May 20, 2015|
|Title||Therapeutic Monoclonal Antibody Lead Optimization and Development Core|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Zhiqiang An|
|Cancer Sites||All Sites|
Antibody therapy represents a major breakthrough in combating human diseases such as cancer. Its impact is reflected by the growing trend of monoclonal antibody drug discovery and development. In 2000, nine of the top 10 medicines were small molecules while only one was a recombinant protein. However, by the end of 2013, seven of the top 10 medicines were antibodies. This trend is continuing as about 50% of the new drugs in various stages of clinical development are antibodies, and cancer therapeutic antibodies constitute a majority. As the discovery of novel cancer targets accelerates, platform technologies to support early stage therapeutic antibody development are in great demand especial...